News >

Nivolumab Shows Marked Activity in Recurrent Metastatic Gynecologic Cancers

Caroline Seymour
Published: Wednesday, Sep 25, 2019

R. Wendel Naumann, MD, director of Minimally Invasive Surgery in Gynecologic Oncology at Carolinas Medical Center, Atrium Health

R. Wendel Naumann, MD

Nivolumab (Opdivo) monotherapy demonstrated promising activity in a small number of patients with recurrent or metastatic cervical, vaginal, and vulvar cancer, according to results of the gynecologic cancer cohort of the phase I/II CheckMate-358 trial (NCT02488759).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication